EVP, Chief Financial Officer · SAB Biotherapeutics, Inc. (SABS)

Michael King Jr.

FY2023 is the first fiscal year CompBrief holds for Michael King Jr. as a named executive officer of SAB Biotherapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$721,988

Salary $60,577Stock awards $0

2nd of 5 named executive officers at SAB Biotherapeutics by FY2023 total.

5 named officers on file for SAB Biotherapeutics, FY2023

Michael King Jr.’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SAB Biotherapeutics’s whole pay program stands against its peers

  • SAB Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SABS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 30, 2024 (DEF 14A).

Free

Get Michael King Jr.’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael King Jr. compensation by year

SAB Biotherapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as SAB Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$60,577
Bonus$0
Stock awards$0
Option awards$661,411
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$721,988

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed May 30, 2024, accession 0000950170-24-066767, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0000950170-24-066767. Every figure is read from that document and cited to the page and table it appears in. Filed May 30, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option85,000—$7.98

Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

SAB Biotherapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Alexandra KropotovaEVP, Chief Medical Officer$921,575
Michael King Jr. · this pageEVP, Chief Financial Officer$721,988
Eddie SullivanPresident$605,157
Samuel ReichChairman of the Board of Directors and Chief Executive Officer$565,798
Christoph BauschEVP, Chief Operating Officer$549,323

The full SAB Biotherapeutics compensation record

free company brief

This page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael King Jr.'s compensation dossier · One-time report. No refunds.